Inovio Pharmaceuticals, Inc.
INOStock
$1.12−10.69%52W
Market Cap$94.61M
P/E—
Div yield—
Beta1.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.40%
Price vs S&P 500 (4W)4.81%
VGM Score27.20
Market Capitalization$94.61M
Earnings Surprise History
Q1 26-0.28est. -0.35
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
3.89
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INOInovio Pharmaceuticals, Inc. | D | F | C | $1.12 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies for HPV-associated diseases, cancer, and infectious diseases. The company's proprietary electroporation technology enables targeted delivery and enhanced immunogenicity of its DNA medicine candidates.